Cell and Gene Manufacturing and Logistics

  1. Process Validation: Working Toward Harmonization Of Terms Used To Identify Validation Lots 10/31/2025

    The terms “confirmatory" and "conformance" batches are inconsistently used in the industry. Since process validation is essential for maintaining compliance and detecting variability, we must work toward harmonization of the terms to avoid confusion.

  2. Advance Your Cell And Gene Therapy With Benchtop Automation 10/30/2025

    Automate better biology and accelerate product development with a benchtop platform designed to scale cell therapy manufacturing from R&D to GMP with flexible bioreactors and sterile fluid transfer.

  3. Trends Shaping The Future Of Cell And Gene Therapy Manufacturing 10/30/2025

    Discover how automation and digitalization are transforming cell and gene therapy with scalable, decentralized manufacturing and smarter market navigation.

  4. Meet The Latest Member Of The Oligo Synthesis Family 10/30/2025

    Discover a system with a flexible synthesis scale, intuitive software, and robust process control that is ideal for labs moving from research to production.

  5. Research-Scale Oligonucleotide Workflow 10/30/2025

    Get a clear view of oligonucleotide development from synthesis to purification and filtration with practical insights to help you streamline workflows and stay ahead in the fight against disease.

  6. Improve Viral Titers In Your AAV Program With A Flexible Media System 10/29/2025

    Achieve superior AAV production yields in suspension HEK293 cells. This chemically-defined media system offers flexibility, robust growth, and can boost viral titers up to 4x.

  7. Nunc Cell Factory Systems 10/29/2025

    Transitioning to biobased materials in cell culture reduces reliance on virgin fossil fuel feedstocks and helps meet Scope 3 emission reduction goals, offering a sustainable path for biomanufacturing.

  8. Streamlining Tech Transfer And Advancing Next Generation CAR T Therapies 10/29/2025

    In this final segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman emphasizes that early engagement between R&D, process development, and manufacturing teams is critical for smooth tech transfer to CDMOs, including using scale-down models, documenting processes thoroughly, and collaborating closely with CDMO staff.

  9. Balancing Innovation And Flexibility In Early Cell Therapy Manufacturing Technologies 10/29/2025

    In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman explains that introducing advanced analytics, automation, and digital tools early can strengthen process control and sterility, but startups must weigh innovation against practical constraints.

  10. The Importance Of Early Manufacturing Choices And Simple Flexible Process Design 10/29/2025

    In this first segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene explore how early manufacturing decisions influence long-term success in cell therapy development.